This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2025 Jul 11;15(1):25059.

doi: 10.1038/s41598-025-09484-z.

Correction: Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate

Renshi Kawakatsu¹, Kenjiro Tadagaki¹, Kenta Yamasaki¹, Tatsushi Yoshida²

Affiliations

Affiliations

¹ Department of Biochemistry and Molecular Biology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
² Department of Biochemistry and Molecular Biology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan. yoshida@koto.kpu-m.ac.jp.

PMID: 40646095
PMCID: PMC12254250
DOI: 10.1038/s41598-025-09484-z

Published Erratum

Correction: Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate

Renshi Kawakatsu et al. Sci Rep. 2025.

. 2025 Jul 11;15(1):25059.

doi: 10.1038/s41598-025-09484-z.

Authors

Renshi Kawakatsu¹, Kenjiro Tadagaki¹, Kenta Yamasaki¹, Tatsushi Yoshida²

Affiliations

¹ Department of Biochemistry and Molecular Biology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
² Department of Biochemistry and Molecular Biology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan. yoshida@koto.kpu-m.ac.jp.

PMID: 40646095
PMCID: PMC12254250
DOI: 10.1038/s41598-025-09484-z

No abstract available

PubMed Disclaimer

Figures

Fig. 5 — Fig. 5
Caspase activation was induced by the combination of venetoclax and NaB. KG-1 was treated with venetoclax alone or the combination with venetoclax and NaB for 48 h. (A) Western blotting of PARP. Cell lysates were extracted and western blotting was performed. Upper panel; PARP, Lower panel; actin. Molecular weight marker was shown at the left side. The PARP-cleaved form generated by caspase activation was indicated by an arrow. Original blots are presented in Supplemental Fig. 3. Quantification of band intensity was shown in Supplemental Fig. 4. (B) Trypan blue dye exclusion assay to examine the rate of live or dead cells. (C) Cell morphologies were observed using a microscope. (D,E) Cell cycle analyses of cells stained with PI using a flow cytometry. A bar graph with triplicate data (D) and representative histograms (E) were shown. The data was n = 3 ± S.D.. Vene; venetoclax.

See this image and copyright information in PMC

Erratum for

Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate.
Kawakatsu R, Tadagaki K, Yamasaki K, Yoshida T. Kawakatsu R, et al. Sci Rep. 2024 Feb 29;14(1):4975. doi: 10.1038/s41598-024-55286-0. Sci Rep. 2024. PMID: 38424468 Free PMC article.

Similar articles

Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate.
Kawakatsu R, Tadagaki K, Yamasaki K, Yoshida T. Kawakatsu R, et al. Sci Rep. 2024 Feb 29;14(1):4975. doi: 10.1038/s41598-024-55286-0. Sci Rep. 2024. PMID: 38424468 Free PMC article.
[Clinical Characteristics of Acute Leukemia Patients with PICALM∷MLLT10 Fusion Gene Positivity and Prognostic Analysis of Combined Venetoclax Targeted Therapy].
Cai CS, Yao Z, Xu MZ, Li Z, Wu YJ, Xue SL. Cai CS, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Jun;33(3):711-719. doi: 10.19746/j.cnki.issn.1009-2137.2025.03.013. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025. PMID: 40613160 Chinese.
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
Fleischmann M, Jentzsch M, Brioli A, Eisele F, Frietsch JJ, Eigendorff F, Tober R, Schrenk KG, Hammersen JF, Yomade O, Hilgendorf I, Hochhaus A, Scholl S, Schnetzke U. Fleischmann M, et al. Ann Hematol. 2025 Jan;104(1):285-294. doi: 10.1007/s00277-024-06048-5. Epub 2024 Oct 25. Ann Hematol. 2025. PMID: 39453477 Free PMC article.
Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
He H, Wen X, Zheng H. He H, et al. Hematology. 2024 Dec;29(1):2343604. doi: 10.1080/16078454.2024.2343604. Epub 2024 May 4. Hematology. 2024. PMID: 38703055
The efficacy and safety of venetoclax combined with decitabine in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis.
He F, Tian T, Qiao S, Xing L. He F, et al. Clin Exp Med. 2025 Jul 9;25(1):239. doi: 10.1007/s10238-025-01794-w. Clin Exp Med. 2025. PMID: 40632299 Free PMC article.

See all similar articles

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central